Chong Kun Dang Pharmaceutical Corp. 185750

KRX · South Korea · Health Technology

KRW 65,200.00+1,000.00 (+1.56%)

Market closed· Oct 1, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Chong Kun Dang Pharmaceutical Corp. 185750

KRX · South Korea · Health Technology

KRW 65,200.00+1,000.00 (+1.56%)

Market closed· Oct 1, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-28.51% · 6MFull-screen chart

Open KRW 64,700.00High KRW 65,400.00Low KRW 64,100.00Close KRW 65,200.00Volume 14.89K

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: KRW 64,200.00
Volume: 0
Market cap: KRW 845.90B
P/E (TTM): 10.9
Dividend yield (annualized): 0.78%
Next earnings date: 2026-11-12
Avg. volume (1Y): 32.94K

Performance

1 week

-1.38%

1 month

-6.25%

3 months

-6.52%

6 months

-27.45%

Year to date

-22.10%

1 year

-20.30%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: South Korea
Exchange: KRX
Shares outstanding: 13.18M
Employees: 2,304
ISIN: KR7185750007
Beta: 0.17

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceAug 19, 2026

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

Encinitas, California--(Newsfile Corp. - August 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora") today announced that it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation (CKD). CKD, based in Seoul, is one of South Korea's leading pharmaceutical companies. Under the agreement, Kiora will receive a $1 million upfront payment and is eligible to receive development and...

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.